BACKGROUND: Tumour-specific cytotoxic T lymphocytes (CTLs) can be activated in vivo by vaccination with dendritic cells (DCs). However, clinical responses to DC-based vaccination have only been observed in a minority of patients with solid cancer. Combination with other treatment modalities such as chemotherapy may overcome immunoresistance of cancer cells. It has been shown previously that gemcitabine sensitises human pancreatic carcinoma cells against CTL-mediated lysis. Here, a murine pancreatic carcinoma model was used to investigate whether combination with gemcitabine increases therapeutic efficacy of DC-based vaccination. METHODS: Bone marrow-derived DCs from C57BL/6 mice were loaded with UV-irradiated, syngeneic Panc02 carcinoma cells and were administered subcutaneously. For prophylactic vaccination, mice were vaccinated three times at weekly intervals prior to tumour challenge with Panc02 cells. Therapeutic vaccination was started when tumours formed a palpable nodule. Gemcitabine was administered intraperitoneally twice weekly. RESULTS: Prophylactic DC-based vaccination completely prevented subcutaneous and orthotopic tumour development and induced immunological memory as well as tumour antigen-specific CTLs. In the subcutaneous tumour model, therapeutic DC-based vaccination was equally effective as gemcitabine (14% vs 17% survival at day 58 after tumour challenge; controls, 0%). Combination of the two strategies significantly increased survival of tumour-bearing mice (50% at day 58 after tumour challenge). DC-based vaccination also prevented death from pulmonary metastatisation after intravenous injection of Panc02 cells. CONCLUSION: DC-based immunotherapy may not only be successfully combined with gemcitabine for the treatment of advanced pancreatic carcinoma, but may also be effective in preventing local recurrence or metastatisation in tumour-free patients.
BACKGROUND:Tumour-specific cytotoxic T lymphocytes (CTLs) can be activated in vivo by vaccination with dendritic cells (DCs). However, clinical responses to DC-based vaccination have only been observed in a minority of patients with solid cancer. Combination with other treatment modalities such as chemotherapy may overcome immunoresistance of cancer cells. It has been shown previously that gemcitabine sensitises humanpancreatic carcinoma cells against CTL-mediated lysis. Here, a murinepancreatic carcinoma model was used to investigate whether combination with gemcitabine increases therapeutic efficacy of DC-based vaccination. METHODS: Bone marrow-derived DCs from C57BL/6 mice were loaded with UV-irradiated, syngeneic Panc02 carcinoma cells and were administered subcutaneously. For prophylactic vaccination, mice were vaccinated three times at weekly intervals prior to tumour challenge with Panc02 cells. Therapeutic vaccination was started when tumours formed a palpable nodule. Gemcitabine was administered intraperitoneally twice weekly. RESULTS: Prophylactic DC-based vaccination completely prevented subcutaneous and orthotopic tumour development and induced immunological memory as well as tumour antigen-specific CTLs. In the subcutaneous tumour model, therapeutic DC-based vaccination was equally effective as gemcitabine (14% vs 17% survival at day 58 after tumour challenge; controls, 0%). Combination of the two strategies significantly increased survival of tumour-bearing mice (50% at day 58 after tumour challenge). DC-based vaccination also prevented death from pulmonary metastatisation after intravenous injection of Panc02 cells. CONCLUSION: DC-based immunotherapy may not only be successfully combined with gemcitabine for the treatment of advanced pancreatic carcinoma, but may also be effective in preventing local recurrence or metastatisation in tumour-freepatients.
Authors: J Banchereau; F Briere; C Caux; J Davoust; S Lebecque; Y J Liu; B Pulendran; K Palucka Journal: Annu Rev Immunol Date: 2000 Impact factor: 28.527
Authors: Jacques Banchereau; Hideki Ueno; Madhav Dhodapkar; John Connolly; Jennifer P Finholt; Eynav Klechevsky; Jean-Philippe Blanck; Dennis A Johnston; A Karolina Palucka; Joseph Fay Journal: J Immunother Date: 2005 Sep-Oct Impact factor: 4.456
Authors: Marc Dauer; Jan Herten; Christian Bauer; Frederik Renner; Katharina Schad; Max Schnurr; Stefan Endres; Andreas Eigler Journal: J Immunother Date: 2005 Jul-Aug Impact factor: 4.456
Authors: Steve Broomfield; Andrew Currie; Robbert G van der Most; Matthew Brown; Ivonne van Bruggen; Bruce W S Robinson; Richard A Lake Journal: Cancer Res Date: 2005-09-01 Impact factor: 12.701
Authors: Josine van Beek; Axel zur Hausen; Sander N Snel; Johannes Berkhof; Elma Klein Kranenbarg; Cornelis J H van de Velde; Adriaan J C van den Brule; Jaap M Middeldorp; Chris J L M Meijer; Elisabeth Bloemena Journal: Am J Surg Pathol Date: 2006-01 Impact factor: 6.394
Authors: Friedrich H Schmitz-Winnenthal; Christine Volk; Kaspar Z'graggen; Luis Galindo; Daniel Nummer; Yvonne Ziouta; Marianna Bucur; Jürgen Weitz; Volker Schirrmacher; Markus W Büchler; Philipp Beckhove Journal: Cancer Res Date: 2005-11-01 Impact factor: 12.701
Authors: Anna K Nowak; Richard A Lake; Amanda L Marzo; Bernadette Scott; William R Heath; Edward J Collins; Jeffrey A Frelinger; Bruce W S Robinson Journal: J Immunol Date: 2003-05-15 Impact factor: 5.422
Authors: Sebastian Kobold; Simon Grassmann; Michael Chaloupka; Christopher Lampert; Susanne Wenk; Fabian Kraus; Moritz Rapp; Peter Düwell; Yi Zeng; Jan C Schmollinger; Max Schnurr; Stefan Endres; Simon Rothenfußer Journal: J Natl Cancer Inst Date: 2015-06-23 Impact factor: 13.506
Authors: Vanaja Konduri; Dali Li; Matthew M Halpert; Dan Liang; Zhengdong Liang; Yunyu Chen; William E Fisher; Silke Paust; Jonathan M Levitt; Qizhi Cathy Yao; William K Decker Journal: Oncoimmunology Date: 2016-07-22 Impact factor: 8.110